Global Statistics

All countries
244,109,329
Confirmed
Updated on 24/10/2021 3:27 am
All countries
219,455,018
Recovered
Updated on 24/10/2021 3:27 am
All countries
4,959,373
Deaths
Updated on 24/10/2021 3:27 am

Global Statistics

All countries
244,109,329
Confirmed
Updated on 24/10/2021 3:27 am
All countries
219,455,018
Recovered
Updated on 24/10/2021 3:27 am
All countries
4,959,373
Deaths
Updated on 24/10/2021 3:27 am

Pfizer Covid-19 Vaccine Safely Boosts Antibodies in Younger Children

Pfizer and its partner BioNTech SE said their Covid-19 vaccine was safe and produced strong antibody responses in children ages 5 to 11 in a large-scale trial, findings that could pave the way to begin vaccinating elementary school children. in a few months.

The long-awaited results offer one of the first looks at how well a Covid vaccine might work for younger children.

Pressure to immunize children has been mounting in the US, where a new school year has started just as the delta variant is driving an increase in cases.

In a trial of 2,268 participants, two injections of a 10-microgram dose (one-third of the adult vaccine) produced antibody levels comparable to those seen in a trial of 16 to 25-year-olds who received the adult dose, the companies. he said, with similar side effects.

Pfizer and BioNTech said they plan to submit the data as part of a short-term request for an emergency use authorization from the US Food and Drug Administration, and share it with regulators in Europe as well.

An authorization would mark an important new phase of the immunization campaign in the US, where the Pfizer vaccine already has full approval for people 16 years and older and is emergency authorized for ages 12-15. And a pediatric clearance could reach millions of older Americans are receiving additional doses to reinforce their initial injections.

Dear reader,

Business Standard has always strived to provide up-to-date information and feedback on developments that interest you and that have broader political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering has only strengthened our determination and commitment to these ideals. Even during these difficult times arising from Covid-19, we remain committed to keeping you informed and up-to-date with credible news, authoritative opinions, and incisive commentary on relevant current affairs.
However, we have a request.

As we fight the economic impact of the pandemic, we need your support even more so that we can continue to bring you more quality content. Our subscription model has received an encouraging response from many of you, who have subscribed to our content online. Increased subscription to our online content can only help us achieve our goals of bringing you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practice the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital editor

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Hot Topics

Related Articles